reported that Immunoscore-biopsy (ISB) which was determined based on densities of CD3+ and CD8+ T cells in rectal cancer biopsy samples could predict response to pre-CRT in patients with rectal cancer. This evidence concerns the gene CD8A and rectal cancer.